• 미생물학회지
• /
• 제52권4호
• /
• pp.482-486
• /
• 2016

차가버섯(Inonotus obliquus)은 다양한 생리활성을 가진 약용버섯으로 항암, 항산화, 항염효능 등을 가진 것으로 보고되었다. EBV 양성 위암은 EBV관련 암 중 가장 빈번하게 나타나는 형태로 EBV 잠복감염이 그 원인이다. 본 연구에서는 차가버섯 주정추출물의 경구투여를 통해 EBV 양성 인간위암(SNU719) 세포주를 면역결핍 쥐에 주입 후 생기는 고형암 생성억제에 대한 효능을 연구하였다. 또한, 실험종료 후, 각각의 종양조직을 절제하여 항종양 억제기전을 탐구하였다. In vivo 종양생성억제 실험에서 차가버섯은 유의적으로 고형암 생성억제 효능을 보였다. 차가버섯이 투여된 동물유래 종양조직에서 세포자멸사와 관련된 p53, p21 및 Bax의 발현이 크게 증가하였으며, 이는 cleaved caspase-9와 cleaved Parp 발현의 상승과 동반하여 항종양 효능이 세포자멸사를 통해 나타남을 제시하였다. 또한, 이러한 항종양 효능은 세포주 내 잠복되어 있는 EBV 바이러스 유전자인 BZLF-1 및 LMP-2의 발현에도 영향을 미치는 것으로 밝혀졌다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권5호
• /
• pp.2555-2558
• /
• 2016

Background: Gastric cancer is the second most common gastrointestinal cancer and is still associated with significant morbidity and mortality due to late presentation and diagnosis at advanced stages. Studies have reported that a variable proportion of gastric cancer is positive for the human epidermal growth factor receptor 2 (HER2) and patients with HER2 positive (HER2 +ve) lesions can benefit from targeted therapy. This study was conducted to assess the prevalence of HER2 +ve gastric cancers in Brunei Darussalam, a developing Southeast Asian nation. Materials and Methods: Patients were identified from the Department of Pathology registry and retrospectively reviewed. HER2 expression was assessed by immunohistochemistry and only those staining 3+were considered positive. Results: Our study included 103 cases (66 males and 37 females) with a mean age of $65.1{\pm}14.8$ years old. There were 14 cases positive for HER2 (10 males and 4 females) giving a prevalence of 13.6%. The HER2 +ve cases were significantly older ($70.6{\pm}19.3$ years old) than the negative cases ($64.2{\pm}13.8$, p=0.041) and had significantly more advanced disease (stages 3 and 4, p=0.026). There were no significant differences in gender distribution, presence of intestinal metaplasia, EBV status, Helicobacter pylori status, tumor location (proximal vs. distal) and degree of tumor differentiation (all p values >0.05). Conclusions: Our study showed that 13.6% of our gastric cancers are positive for HER2, the affected patients being older and having more advanced disease at diagnosis.